A case of morphea following the <scp>COVID</scp>‐19 <scp>mRNA</scp> vaccine: on the basis of viral spike proteins

Various adverse effects particularly cutaneous manifestations associated with different COVID‐19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID‐19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID‐19 vaccination were enrolled in our case‐series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty‐five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18–91) were enrolled in our study. Twenty‐two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new‐onset lichen planus (LP) and 1 (4%) patient manifested LP flare‐up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new‐onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare‐up. Other new‐onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID‐19 vaccines.

show abstract

“…In this regard, Metin et al reported a case of morphea following the administration of the COVID‐19 mRNA vaccine. 19 …”

Section: Discussionmentioning

confidence: 99%

Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases

Shakoei

Kalantari

Nasimi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…” Metin and Celepli mentioned that “ The pathogenesis of post‐vaccination vasculitis remains unclear. To our knowledge, this is the first report of large vessel vasculitis following by BNT162b2 vaccination…… 1 …”

mentioning

confidence: 82%

“…To our knowledge, this is the first report of large vessel vasculitis following by BNT162b2 vaccination…… . 1 ” We agree COVID‐19 vaccination might cause adverse effect and the dermatological problem is a possible example. Metin and Celepli reported an interesting case of vaccine recipient presenting with morphea or localized scleroderma.…”

mentioning

confidence: 83%

“…We would like to share ideas on the publication “A case of morphea following the COVID‐19 mRNA vaccine: on the basis of viral spike proteins. 1 ” Metin and Celepli mentioned that “ The pathogenesis of post‐vaccination vasculitis remains unclear. To our knowledge, this is the first report of large vessel vasculitis following by BNT162b2 vaccination…… .…”

mentioning

confidence: 99%

“…We would like to share ideas on the publication “A case of morphea following the COVID‐19 mRNA vaccine: on the basis of viral spike proteins 1 …”

mentioning

confidence: 99%

See 2 more Smart Citations